@article{WoźnickiLaquaMessmeretal.2022,
  author    = {Wo{\'{z}}nicki, Piotr and Laqua, Fabian Christopher and Messmer, Katharina and Kunz, Wolfgang Gerhard and Stief, Christian and N{\"o}renberg, Dominik and Schreier, Andrea and W{\´o}jcik, Jan and Ruebenthaler, Johannes and Ingrisch, Michael and Ricke, Jens and Buchner, Alexander and Schulz, Gerald Bastian and Gresser, Eva},
  title     = {Radiomics for the prediction of overall survival in patients with bladder cancer prior to radical cystectomy},
  series = {Cancers},
  volume    = {14},
  journal   = {Cancers},
  number    = {18},
  issn      = {2072-6694},
  doi       = {10.3390/cancers14184449},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-288098},
  year      = {2022},
  abstract  = {(1) Background: To evaluate radiomics features as well as a combined model with clinical parameters for predicting overall survival in patients with bladder cancer (BCa). (2) Methods: This retrospective study included 301 BCa patients who received radical cystectomy (RC) and pelvic lymphadenectomy. Radiomics features were extracted from the regions of the primary tumor and pelvic lymph nodes as well as the peritumoral regions in preoperative CT scans. Cross-validation was performed in the training cohort, and a Cox regression model with an elastic net penalty was trained using radiomics features and clinical parameters. The models were evaluated with the time-dependent area under the ROC curve (AUC), Brier score and calibration curves. (3) Results: The median follow-up time was 56 months (95\% CI: 48-74 months). In the follow-up period from 1 to 7 years after RC, radiomics models achieved comparable predictive performance to validated clinical parameters with an integrated AUC of 0.771 (95\% CI: 0.657-0.869) compared to an integrated AUC of 0.761 (95\% CI: 0.617-0.874) for the prediction of overall survival (p = 0.98). A combined clinical and radiomics model stratified patients into high-risk and low-risk groups with significantly different overall survival (p < 0.001). (4) Conclusions: Radiomics features based on preoperative CT scans have prognostic value in predicting overall survival before RC. Therefore, radiomics may guide early clinical decision-making.},
  language  = {en}
}
@article{KunathKrauseWullichetal.2013,
  author    = {Kunath, Frank and Krause, Steffen F. and Wullich, Bernd and Goebell, Peter J. and Engehausen, Dirk G. and Burger, Maximilian and Meerpohl, Joerg J. and Keck, Bastian},
  title     = {Bladder cancer - the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.gov},
  series = {BMC Urology},
  volume    = {13},
  journal   = {BMC Urology},
  number    = {56},
  doi       = {10.1186/1471-2490-13-56},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-122133},
  year      = {2013},
  abstract  = {Background: Uro-oncological neoplasms have both a high incidence and mortality rate and are therefore a major public health problem. The aim of this study was to evaluate research activity in uro-oncology over the last decade. Methods: We searched MEDLINE and ClinicalTrials.gov systematically for studies on prostatic, urinary bladder, kidney, and testicular neoplasms. The increase in newly published reports per year was analyzed using linear regression. The results are presented with 95\% confidence intervals, and a p value <0.05 was considered statistically significant. Results: The number of new publications per year increased significantly for prostatic, kidney and urinary bladder neoplasms (all <0.0001). We identified 1,885 randomized controlled trials (RCTs); also for RCTs, the number of newly published reports increased significantly for prostatic (p = 0.001) and kidney cancer (p = 0.005), but not for bladder (p = 0.09) or testicular (p = 0.44) neoplasms. We identified 3,114 registered uro-oncological studies in ClinicalTrials.gov. However, 85\% of these studies are focusing on prostatic (45\%) and kidney neoplasms (40\%), whereas only 11\% were registered for bladder cancers. Conclusions: While the number of publications on uro-oncologic research rises yearly for prostatic and kidney neoplasms, urothelial carcinomas of the bladder seem to be neglected despite their important clinical role. Clinical research on neoplasms of the urothelial bladder must be explicitly addressed and supported.},
  language  = {en}
}